Kepler Davis, MD
Infectious Disease · Augusta, GANPI 1740357425
Payments from drug & device makers
Across 162 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Merck$684
- Gilead$257
- Octapharma USA, Inc.$146
- Theratechnologies Inc.$135
- AbbVie$111
- plus $725 from 16 others
What the payments were for
- Food & beverage$3,773100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 63 | $1,716 |
| Merck | 33 | $684 |
| Gilead | 11 | $257 |
| Octapharma USA, Inc. | 3 | $146 |
| Theratechnologies Inc. | 6 | $135 |
| AbbVie(2 entities) | 6 | $111 |
| Insmed, Inc. | 5 | $93 |
| Melinta Therapeutics, LLC | 5 | $78 |
| Johnson & Johnson | 5 | $71 |
| La Jolla Pharmaceutical Company | 3 | $58 |
| Astellas Pharma US Inc | 3 | $55 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $51 |
| Shionogi Inc | 2 | $47 |
| Pharming Healthcare, Inc. | 2 | $41 |
| GSK | 2 | $37 |
| Ferring Pharmaceuticals Inc. | 2 | $35 |
| Aimmune Therapeutics, Inc. | 2 | $35 |
| Paratek Pharmaceuticals, Inc. | 2 | $33 |
| EMD Serono, Inc. | 1 | $31 |
| ADMA Biomanufacturing LLC | 1 | $23 |
| Hospira, Inc. | 1 | $22 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,773 in reported general payments places this provider in the 60th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 234 | $850,257 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 97 | $358,252 |
| DovatoDolutegravir Sodium/Lamivudine | 111 | $327,024 |
| DescovyEmtricitabine/Tenofov Alafenam | 105 | $229,487 |
| TivicayDolutegravir Sodium | 64 | $145,826 |
| Daptomycin | 86 | $136,413 |
| JulucaDolutegravir/Rilpivirine | 37 | $123,688 |
| CabenuvaCabotegravir/Rilpivirine | 14 | $105,238 |
| IsentressRaltegravir Potassium | 38 | $77,471 |
| ErtapenemErtapenem Sodium | 96 | $48,441 |
| PrezcobixDarunavir/Cobicistat | 14 | $34,069 |
| MicafunginMicafungin Sodium | 36 | $23,367 |
| Etravirine | 13 | $13,723 |
| Fosfomycin Tromethamine | 22 | $12,050 |
| Vancomycin Hcl | 55 | $8,954 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $257 | $1,079,745339 claims |
| Viiv Healthcare CompanyTriumeq, Dovato, Tivicay, Juluca, Cabenuva | $1,716 | $1,060,027323 claims |
| MerckIsentress | $684 | $77,47138 claims |
| Johnson & JohnsonPrezcobix | $71 | $34,06914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Augusta
- Jose VazquezAugusta$967K
- Cheryl NewmanAugusta$945K
- John RissingAugusta$24K
- Mark MulliganAtlanta$4.6M
- Nadine RouphaelAtlanta$2.4M
- Leila HojatAtlanta$2.2M
- Kimberly WorkowskiAtlanta$2M
- Robin DretlerDecatur$1.8M
- Harold KatnerMacon$1.3M
- Andrew DoldDacula$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.